Lawrence Corey
Affiliations: | University of Washington, Seattle, Seattle, WA |
Area:
Microbiology Biology, Molecular Biology, Cell BiologyGoogle:
"Lawrence Corey"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| McClymont E, Bone J, Orem J, et al. (2023) Increased frequency and quantity of mucosal and plasma cytomegalovirus replication among Ugandan Adults Living with HIV. Plos One. 18: e0287516 |
| Gilbert PB, Huang Y, deCamp AC, et al. (2022) Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nature Medicine |
| Byrne CM, Johnston C, Orem J, et al. (2021) Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads. Plos Computational Biology. 17: e1009072 |
| Gray GE, Bekker LG, Laher F, et al. (2021) Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. The New England Journal of Medicine. 384: 1089-1100 |
| Curlin ME, Shao J, Diaz G, et al. (2020) Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. Vaccine |
| Schiffer JT, Johnston C, Wald A, et al. (2020) An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases. 7: ofaa232 |
| DeRosa S, Edupuganti S, Huang Y, et al. (2020) Robust antibody and cellular responses induced by DNA-only vaccination for HIV. Jci Insight |
| Cohen MS, Corey L. (2020) Combination prevention for COVID-19. Science (New York, N.Y.). 368: 551 |
| Roychoudhury P, Swan DA, Duke ER, et al. (2020) Tissue-resident T cell derived cytokines eliminate herpes simplex virus-2 infected cells. The Journal of Clinical Investigation |
| Laher F, Moodie Z, Cohen KW, et al. (2020) Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. Plos Medicine. 17: e1003038 |